COVID-19 Vaccines: US Distribution Plans Include ‘Data Lake’ For Centralized Tracking

Most vaccines will be distributed centrally by McKesson, but those with ultra-cold storage requirements will be shipped directly from the manufacturer to the vaccination site. Data exchange system will enable public and private databases to talk to each other and help ensure individuals receive timely revaccination with a second dose of the same vaccine regardless of location.

Truck with container on highway, cargo transportation concept. Shaving effect.
Operation Warp Speed is planning for centralized distribution of all but the coldest COVID-19 vaccines. • Source: Shutterstock

The US government’s COVID-19 vaccination strategy includes tracking distribution and administration through a data exchange system that will help ensure timely administration of a second dose for multi-dose vaccines.

This common IT infrastructure, known as a “data lake,” will encompass both public and private databases and could serve as a model for leveraging real-world data from disparate health care

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Vaccines

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.